Dominari Holdings Inc.
DOMH
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and aā¦ read more
Healthcare
Biotechnology
46 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.62
Price-3.32%
-$0.09
1Y
Price
Market Cap
$59.248m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-105.1%
EBITDA Margin-160.2%
Net Profit Margin-80.8%
Free Cash Flow Margin-105.1%
EBITDA Margin-160.2%
Net Profit Margin-80.8%
Free Cash Flow MarginRevenue
$150.797m
+22.5%
1y CAGR+463.6%
3y CAGR+347.7%
5y CAGREarnings
-$47.305m
-110.8%
1y CAGR-42.6%
3y CAGR-32.8%
5y CAGREPS
-$2.98
-89.8%
1y CAGR-3.4%
3y CAGR+7.3%
5y CAGRBook Value
$31.577m
$85.320m
Assets$53.743m
Liabilities$2.744m
DebtDebt to Assets
3.2%
-
Debt to EBITDAFree Cash Flow
-$7.457m
-132.8%
1y CAGR+50.2%
3y CAGR+17.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company